Fig 3. SWCNT/CpG-2 + TMZ treatment increases the proportion of macrophages in the tumor.

(A) Proportion (left panel) and absolute number (right panel) of tumor infiltrating CD20⁺, CD3⁺, NK, MP (CD11b⁺CD45^high) and MG (CD11b⁺CD45^low) cells (unpaired two-tailed t-test * P < 0.05 and ** P < 0.01, n = 3). (B) Representative flow cytometry data of percent MP (CD11b⁺CD45^high) and MG (CD11b⁺CD45^low) cells in tumor after treatments. (C) Representative fluorescent imaging of tumor infiltrating CD3⁺, CD8⁺, and CD11b⁺ cells 10 days after treatment (14 days after tumor implantation). Scale bar is 100 μm.